Allergan cautions against exchange as Valeant gets down to the 'facts'

Save

Allergan's board has already rejected Valeant's $53 billion buyout bid, prompting the wannabe-acquirer to take the proposal directly to shareholders. Unsurprisingly enough, Allergan's board doesn't like that too much, either. And if you ask Valeant, it's twisting the facts to get shareholders on its side.